<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086019</url>
  </required_header>
  <id_info>
    <org_study_id>BN-AdB-RINCAL-2013</org_study_id>
    <nct_id>NCT02086019</nct_id>
  </id_info>
  <brief_title>Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes</brief_title>
  <acronym>RINCAL</acronym>
  <official_title>A Prospective Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brighton and Sussex University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brighton and Sussex University Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For octogenarian patients with NSTEMI (non-ST segment elevation myocardial infarction) an
      invasive-guided strategy will prove superior to a conservative strategy with respect to a
      combined endpoint of all cause mortality and non-fatal myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>1 year</time_frame>
    <description>The cause of death will be adjudicated as being due to cardiovascular causes, non cardiovascular causes, or undetermined causes.
Cardiovascular Death includes sudden cardiac death, death due to acute myocardial infarction, death due to heart failure or cardiogenic shock, death due to stroke or death due to other cardiovascular causes
Non-Cardiovascular Death is defined as any death not covered by cardiac death or vascular death.
Undetermined cause of death refers to a death not attributable to one of the above categories of cardiovascular death or to a non-cardiovascular cause.
N.B For this trial all deaths with undetermined causes will be included in the cardiovascular category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>non-fatal myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>The ESC/ACC (European Society of Cardiology and the American College of Cardiology) definition of myocardial infarction will be applied, including the special circumstances of same admission myocardial re-infarction, or myocardial infarction peri-PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unplanned revascularisation</measure>
    <time_frame>1 years</time_frame>
    <description>Shall be deemed to have occurred at follow-up if any coronary vessel requires or undergoes attempted repeat revascularisation with either balloon angioplasty, stenting, or coronary artery bypass grafting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent Stroke</measure>
    <time_frame>1 year</time_frame>
    <description>A stroke is a loss of neurological function caused by an ischemic or hemorrhagic event with residual symptoms at least 24 hours after onset or leading to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>1 year</time_frame>
    <description>BARC (Bleeding Academic Research Consortium) definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deterioration of renal function during hospital admission</measure>
    <time_frame>During index admission</time_frame>
    <description>Worsening renal function is an absolute increase in serum creatinine of â‰¥ 0.3mg/dl (26.5 umol/l) at any time during hospitalization compared to the valve obtained at admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina symptoms (3 months; 1yr)</measure>
    <time_frame>3 months and 1 year</time_frame>
    <description>CCS (Canadian Cardiovascular Society Classification of angina) grading of angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>ARC definition of stent Thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>2,3 and 4 year</time_frame>
    <description>Cardiac and non cardiac mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission for ACS/STEMI</measure>
    <time_frame>At 3, 6 and 12 months and at 2,3 and 4 years</time_frame>
    <description>ESC/ACC definition ACS/STEMI (Acute coronary syndrome/ST-segment elevation myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital major complications</measure>
    <time_frame>At 3, 6 and 12 months and at 2,3 and 4</time_frame>
    <description>In hospital major complications defined as death, myocardial infarction, stent thrombosis, target restenosis, repeat target- and non-target vessel-related percutaneous coronary intervention, target lesion revascularization, coronary artery bypass surgery and stroke.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Conservative Arm- Medical therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive Arm-angiogram with PCI or CABG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conservative Arm</intervention_name>
    <description>crossover to angiogram only if predefined criteria met</description>
    <arm_group_label>Conservative Arm- Medical therapy</arm_group_label>
    <other_name>low molecular weight heparin,</other_name>
    <other_name>aspirin,</other_name>
    <other_name>clopidogrel,</other_name>
    <other_name>beta blocker (Bisoprolol or equivalent)</other_name>
    <other_name>ACE inhibitor (Ramipril or equivalent)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Invasive Arm</intervention_name>
    <description>angiogram with PCI or CABG revascularisation if appropriate</description>
    <arm_group_label>Invasive Arm-angiogram with PCI or CABG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AGE&gt;80 Non-STEMI - characteristic chest pain accompanied by

          -  Typical ischaemic ECG changes

          -  A troponin rise

        Suitable for conservative or invasive strategy

        Exclusion Criteria:

          -  Lack of suitability for whatever clinical reason to be randomised eg dementia,
             co-morbidity

          -  Acute STEMI

          -  Cardiogenic shock

          -  Platelet count =50 x 109/mm3

          -  Patient life expectancy &lt; 1 year

          -  Known allergies to clopidogrel, aspirin, heparin, stainless steel, IV contrast or
             stent drug elutant

          -  Recent major GI haemorrhage (within 3 months)

          -  Any previous cerebral bleeding episode

          -  Participation in another investigational drug or device study

          -  Patient unable to give consent

          -  Clinical decision precluding the use of stents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicola Skipper</last_name>
    <phone>01273 696955</phone>
    <phone_ext>7673</phone_ext>
    <email>Nicola.Skipper@bsuh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adam deBelder, MD</last_name>
    <phone>01273 696955</phone>
    <phone_ext>4897</phone_ext>
    <email>adam.debelder@bsuh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Skipper</last_name>
      <phone>01273 696955</phone>
      <phone_ext>7673</phone_ext>
      <email>Nicola.Skipper@bsuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Adam deBelder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brighton and Sussex University Hospitals NHS Trust</investigator_affiliation>
    <investigator_full_name>Adam de Belder</investigator_full_name>
    <investigator_title>Consultant Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Revascularisation, octogenarian,acute coronary syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

